fbpx

Blog

PSA congratulates Dr Nicole Higgins, incoming President of RACGP

12 September 2022

 

The Pharmaceutical Society of Australia (PSA) National President Dr Fei Sim welcomes and congratulates Dr Nicole Higgins on her election as President of the Royal Australian College of General Practitioners (RACGP).

 

“I look forward to working with Dr Higgins on the many challenges facing the health sector to achieve better health outcomes for Australians.

 

“In particular, I look forward to discussing pharmacists’ scope of practice, and how  general practitioners and pharmacists as primary healthcare providers can work collaboratively to strengthen our primary healthcare workforce capacity and capability.

 

“The Australian health system is under enormous pressure, with workforce problems creating a GP access crisis in many areas. As a health system, we need to work together collaboratively to enable all healthcare professionals to practice to their top of scope in order to ease some of this pressure. In practice, pharmacists and GPs work well together and complement each other’s roles.

 

“PSA and RACGP share a common goal – to improve the health and wellbeing of Australians. We must put patients and patient outcomes first and work together toward healthier communities.

 

“Finally, I thank Adj. Professor Karen Price for her service and contributions during a particularly turbulent time for the health care sector. I wish her the best for the next chapter,” Dr Sim concluded.

 

 

 

Media contact:   Georgia Clarke   M: 0410 505 315     E: georgia.clarke@psa.org.au

Growth in pharmacy workforce urgently needed to better serve the health system

30 August 2022

 

National President of the Pharmaceutical Society of Australia (PSA) Dr Fei Sim has today called for the Australian Federal Government to urgently invest into growing workforce capacity in pharmacy, ahead of this week’s Jobs and Skills Summit.

 

Despite being the only peak body representing all pharmacists in Australia, PSA has not been invited to attend the Jobs and Skills Summit, after the entire pharmacy sector was also snubbed from the Health Minister’s recent Health Workforce Summit. 

 

“Growth in pharmacy workforce capacity is urgently needed to meet the demands of our patients, communities and health system,” Dr Sim said.

 

“Just like other industries, labour shortages are affecting pharmacies and putting further strain on already exhausted pharmacists.

 

“We have been on the frontlines for two and a half years, keeping our heads above water and dealing with workforce shortages to keep our communities safe. Now is the time for serious action to boost the pharmacist workforce. 

 

“There are persistent challenges in recruiting and retaining pharmacists across all settings, with many telling us that low wages, in some areas, are pushing them away from practice.


“Prime Minister Anthony Albanese again thanked healthcare workers in his address at the National Press Club, but the sector needs leadership and action, not more thanks.


“If working conditions do not improve across the board, the expertise of pharmacists will become inaccessible to our communities. We need leadership from the Federal Government to keep pharmacists on the ground delivering frontline health care and medicine safety.

 

“The Federal Government needs to invest in a whole of profession workforce strategy, working with pharmacists and peak bodies to create attractive and rewarding careers. PSA is ready and willing to work with government to ensure our pharmacist workforce can meet the demands of the future.


“We want to see a plan that puts pharmacists, as the most accessible health professional, at the forefront of health care and allow pharmacists to continue to work with GPs and other healthcare professionals to deliver accessible and safe care to all Australians,” Dr Sim concluded.

 

 

Media contact:   Georgia Clarke   M: 0410 505 315     E: georgia.clarke@psa.org.au

RADIO INTERVIEW: Pharmacists role in primary health care

Dr Fei Sim, PSA National President on Radio 2SM

17 August 2022

 

PRESENTER: I welcome along today to join us from the Pharmaceutical Society of Australia National President Dr Fei Sim… Welcome Dr Fei how are you?

 

DR FEI SIM: Good afternoon, thank you so much for having me.

 

PRESENTER: You’re most welcome. I said that was my prediction , and that came from what we went through in the last couple of years with COVID-19 – how that impacted us and our health – and really the role that our chemists and pharmacies played in stepping up and helping people out. Helping them out with flu symptoms, to get a jab, and the role they played there. Do you think I’m looking toward the next five years as correct in what I say?

 

DR FEI SIM: You raise a really good point there, it’s almost like you’ve got a crystal ball in front of you . I think we can all agree that because of COVID-19, you know COVID-19 has really changed how health professionals practice, but more importantly it has how Australians like to seek health care. What we’re seeing is that the Australian health system is under enormous pressure and in your introduction you mentioned the critical issue we have at the moment which is a GP access crisis with some of the reports we’re receiving saying that wait times are up to four to five weeks. COVID-19 has seen people come through community pharmacy doors, coming to speak to community pharmacists, as their primary health care providers, so I think your prediction there is definitely right and that pharmacists are ready and are here to provide a greater primary health care role in the community.

 

PRESENTER: Dr Fei can you give me an overview of what we’re facing at the moment and what the doctors are facing with the bulk billing issue?

 

DR FEI SIM: We all agree that at the moment that there is a GP access crisis, and based on the latest national survey less than fourteen per cent of medical graduates want to go into General Practice. So, the issue is here to stay and of course adding in bulk billing issues it really is going to affect consumer’s health seeking behaviour or the affordability of seeking health care. As a health system as a whole we need to enable all healthcare professionals to practice to their top of scope, so in this case for instance there are things that a pharmacist can assist with to better serve the health system, for instance, you know, vaccinations, minor ailment management and triaging people so we can reduce unnecessary emergency department and GP presentations. Pharmacists can help with renewing prescriptions for people who are on long term medications, for instance, or even collaborative prescribing. All of this is to free up valuable time of our GPs because our GPs are one of the most highly skilled and highly trained providers, and we need them to be doing more.

 

PRESENTER: With our daily health needs, one of the biggest requirements as you go in with ongoing health concerns is getting your script filled, and to go to a doctor just to get your script filled or to go along those lines, and then to find that you’re going to a doctor who is having issues with bulk billing … Is this an area you think we’ll be leaning more toward a more support role by the chemists and pharmacists assisting where you might not have to go to a doctor in the future and have that consulting and health relationship with pharmacists?

 

DR FEI SIM: That certainly is one of the innovative ways to better serve the health system and of course there will be different patient needs so going by the example you gave there, if someone has a chronic medical condition and they’ve been stabilised on a long-term medicine… The stats are telling us that the average Australian visits a community pharmacy eighteen times a year, they’re already going to their pharmacists, so provided that their medical conditions are stabilised and they’ve been stabilised on their long term medication then yes, in those instances pharmacists can assist in renewing those prescriptions, doing monitoring, but at the same time liaising on the ground with their GP if there’s anything that requires referral. The pharmacist can then facilitate referrals to a GP, that way it frees up GP’s time to undertake more complex cases. So, all together the main message here is that we need to work together at a primary health care level to prevent emergency department and hospitalisations so our whole health system can be more sustainable.  

 

PRESENTER: Do you see more of a stronger collaborative role between the GPs and our pharmacists in the future?

 

DR FEI SIM: Well, what I can share is that on the ground pharmacists and GPs work very well together, especially during COVID-19, you know, we have so many examples of where pharmacists work so closely with their GPs. If a GP is seeing a patient through telehealth, if the patient needs any additional support, GPs actually work really well with the pharmacists. And pharmacists are well trained, you know, they know whats within their scope of practice but also knows trigger points where someone needs to be referred to their GP and the whole triaging process and prioritisation will help people who need to see their GP first get to do that. Then other people who have their condition stabilised and require monitoring if instance, the those things can be managed definitely by a pharmacist as part of routine practice.  It’s already happening at the moment, it’s about normalising and formalising that moving forward.

 

PRESENTER: Dr Fei, COVID-19 really opened our eyes to the services that our chemists and pharmacists can offer us, can you tell me what we might look at as expanded services that we may be able to utilise from our chemists and pharmacists in the future?

 

DR FEI SIM: Well, during COVID-19 pharmacists actually kept their doors open, and we’ve had that health needs where we need as many people in our public be vaccinated, even if I use vaccination as an example, but we’ve really stepped up to ensure that we can vaccinate as many people as we can in our communities to reach the vaccination target. So definitely I do see pharmacists playing an expanded role to other types of vaccines as well as other services like minor ailment management, and the example you gave in your introduction about cold and flu symptoms… you know, you should be going to your pharmacist first and allow pharmacist to triage that first. Also people on chronic medications to actually see their pharmacists for ongoing prescriptions.

 

PRESENTER: Dr Fei, our health needs are so many and varied at the moment in Australia, everything from the paediatrics and new childbirth issues in a new baby, weight issues in Australians, right through to diabetes issues and type two diabetes… all these issues I believe are things at the front of mind for chemist and pharmacists?

 

DR FEI SIM: Yes absolutely, so there is definitely already a trend now for pharmacists to be doing more and offering more professional services. So the examples that you gave there, we’re doing a lot more health screenings. For instance, screening and monitoring people for their blood glucose levels, for their cholesterol levels, and if they require weight management or even smoking cessation, or infant and child health, you know, all of these are about bridging the gap and filling in the gaps but also at the same time making sure that if the person requires additional specialist care that the pharmacist can then facilitate that referral.

 

PRESENTER: Joining us this afternoon from the PSA this afternoon, Dr Fei Sim, thank you for joining us…

 

ENDS

ACT Budget neglects frontline pharmacists

3 August 2022

 

The Pharmaceutical Society of Australia (PSA) has labelled the ACT Government’s 2022-23 Budget as insufficient, ignoring pleas from Canberra’s pharmacists for more support to deliver vaccinations.

 

PSA ACT Branch President Olivia Collenette MPS says that this Budget has abandoned the pharmacists who kept the community safe during COVID-19 and missed a key opportunity to invest in community health.

 

“The ACT Budget has yet again ignored the opportunity to invest in our health system and improve the accessibility of health care to Canberrans,” she said.

 

“Throughout the pandemic, pharmacists remained the most accessible health care professional in our communities, remaining open while others closed their doors and have shown their dedication to the wellbeing of Canberrans.

 

“PSA’s 2022-23 Budget Submission urged the ACT Government to improve patient access by increasing the range of vaccinations provided by pharmacists. This simple regulatory change that could save the lives of Canberrans has been overlooked despite the clear benefits to the community.

 

“The ACT has the most stringent restrictions in the country when it comes to which vaccinations pharmacists can administer, despite pharmacists having been on the frontline of the COVID-19 vaccination rollout throughout the pandemic.

 

“Pharmacists just over the border in New South Wales are able to provide meningococcal and human papillomavirus vaccinations, but not here in the ACT. Canberrans deserve improved accessibility to these vaccinations through their local pharmacy, and our pharmacists deserve the government’s confidence.

 

“Investment in pharmacists will improve the care Canberrans receive from the wider health system and has the potential to reduce the increasing number of Canberrans presenting to emergency departments with minor ailments as well as assisting with current workloads and wait times being experienced by GP clinics.

 

“We urge the ACT Government to reconsider its needless restrictions and give Canberra’s pharmacists the tools to provide world class care to our communities.”

 

 

Media contact: Georgia Clarke   M: 0410 505 315     E: georgia.clarke@psa.org.au

Big Tobacco has no place in Australian healthcare

3 August 2022

 

The Pharmaceutical Society of Australia (PSA) has strongly denounced the reported introduction of a financial incentive program for dispensing nicotine vaping products.

 

Early reports claim that Philip Morris International (PMI) is looking to provide payments to pharmacists to dispense its “VEEV” vaping product.

 

PSA National President Dr Fei Sim has categorically rejected the program, urging pharmacists not to participate in the proposed scheme.

 

“No healthcare professional should accept financial incentives or support from a tobacco company. Big tobacco cannot, and should not, be trusted with the health of Australians.

 

“PMI’s offer of financial kickbacks shows clear contempt for our profession and our dedication to the health and wellbeing of our communities. It’s galling PMI are promoting these products while they remain unregulated and unregistered. No nicotine vapes are registered as medicines in Australia.

 

Nicotine vaping products have not been approved for use by the Therapeutic Goods Administration (TGA) and remain unregulated in Australia, however, patients may access unregistered liquid nicotine products with a prescription from their doctor.

 

“There are currently no nicotine vaping products registered on the Australian Register of Therapeutic Goods, and no company should be advertising unregulated products to Australian healthcare professionals.

 

“Do not confuse a commercially motivated decision from a large multi-national tobacco company as a decision of Australian pharmacists.

 

“TGA has provided clear advice to pharmacists and the health sector – nicotine vaping does not provide substantial benefits to patients as a smoking cessation tool, and nicotine vaping products are not a first-line option for smoking cessation.

 

“PSA provides support and professional practice guidelines for Australian pharmacists to provide smoking cessation support.  

 

“It is not the role of health professionals, including pharmacists, to recommend unregulated therapeutic goods to patients, and PSA calls on any healthcare organisations that have financial agreements with Big Tobacco to terminate these agreements immediately.

 

To access the Guidelines for Pharmacists Providing Smoking Cessation Support, please visit this link. Further information is also available on the TGA website.

 

Media contact: Georgia Clarke   M: 0410 505 315     E: georgia.clarke@psa.org.au

PSA22 comes to a close, PSA23 announced

31 July 2022

 

 

 

The Pharmaceutical Society of Australia (PSA) has today closed the leading education and professional development conference for pharmacists, PSA22, in Sydney. The conference brought hundreds of Australian pharmacists together to further their professional education and discuss the major issues facing the profession.

 

PSA National President Dr Fei Sim said the conference was a great opportunity for pharmacists to come together, face to face after three years.

 

“Pharmacists played a significant role in the health and wellbeing of Australians, having been on the front lines of the COVID-19 response, and delivering more than 8 million COVID-19 vaccination doses to date,” Dr Sim said.

 

“PSA22 has been a great opportunity for pharmacists from all around Australia to reconnect and celebrate what makes our profession great.

 

“I was proud to officially launch the Medicine Safety: Disability Care report on Friday, the fifth in PSA’s Medicine Safety Series.

 

“The Medicine Safety: Disability Care report identifies the real and significant issues Australians living with disability face. It is our duty, as healthcare professionals, to keep working to make care accessible and appropriate for everyone.

 

“PSA was also proud to give members the opportunity to hear directly from the Federal Minister for Health and Aged Care, Mark Butler MP, about the incoming government’s agenda, and how we can continue to support the health and well-being of Australians.

 

“We were also able to recognise and celebrate our hardworking profession through a series of awards presented to outstanding pharmacists.”

 

The 2022 award winners are:

  • Symbion Pharmacist of the Year – A/Prof Faye McMillan (NSW)
  • Symbion Early Career Pharmacist of the Year – Deborah Hawthorne (VIC)
  • Symbion Lifetime Achievement Award – Terence White AO and Rhonda White AO (QLD)
  • MIMS Intern Pharmacist of the Year – Shaylee Mills (WA)
  • Locumate Locum Pharmacist of the Year – Sean Richardson (SA)
  • Viatris Pharmacy Student of the Year – Haylee Shaw (Tas.)
  • APSA Most Outstanding Oral Presentation winner – Lily Pham (NSW)
  • APSA Most Outstanding Poster Presentation winner – Oya Gulal (Vic.)

 

“Congratulations again to all the 2022 award winners and newly inducted Fellows of the Society and thank you to all the panellists, speakers, staff and volunteers who made PSA22 happen.”

 

Dr Sim also announced that PSA23 will be held in Sydney, NSW in July 2023.

 

“It is so valuable to come together, share our experiences as pharmacists from a range of settings, and learn from one another. We cannot wait to see you next year.”

 

Media contact: Georgia Clarke   M: 0410 505 315     E: georgia.clarke@psa.org.au

PSA22: Intern of the Year and Locum of the Year awards

30 July 2022

 

The Pharmaceutical Society of Australia (PSA) is proud to announce the 2022 Intern Pharmacist of the Year and Locum Pharmacist of the Year, which were awarded at PSA22’s plenary session this morning.

 

Shaylee Mills has been awarded the 2022 PSA MIMS Intern Pharmacist of the Year.

 

Sean Richardson has been awarded the 2022 PSA Locumate Locum Pharmacist of the Year.

 

The PSA MIMS Intern Pharmacist of the Year Award recognises intern pharmacists who show outstanding performance in their development as professional pharmacists.

 

“Shaylee Mills has demonstrated her enthusiasm and innovation as an intern pharmacist, and the importance of team work when delivering health services in rural and remote parts of Western Australia,” PSA National President Dr Fei Sim said.

 

“Shaylee has made positive contribution to the health and wellbeing of her local community in the Kimberley region, especially in response to COVID-19, when she worked alongside a team of dedicated senior pharmacists and mentors.”

 

“Shaylee’s passion to improve rural healthcare is evident, as she advocates for more students and interns to consider undertaking a rural placement/internship, contributing to rural workforce capacity.”

 

MIMS CEO Robert Best also congratulated Shaylee, reaffirming MIMS commitment to supporting the next generation of pharmacists.

 

“MIMS acknowledges that pharmacists are the cornerstone of advising, educating and dispensing medicines across Australia, and view the pharmacy profession as the most important and pivotal part of our medicines ecosystem when dealing with consumers and patients,” he said.

 

“For nearly six decades, MIMS has been the most trusted provider of drug and medicines information across the Australian healthcare industry.

 

“It’s this longevity of use that compels MIMS to ensure that Interns who are driving the future of Pharmacy can trust MIMS to stand side-by-side with them as a resource partner.”

 

The PSA Locumate Locum Pharmacist of the Year Award recognises the incredible impact locum pharmacists make all over Australia.

 

“I’m proud to award Sean Richardson with PSA’s first ever Locum Pharmacist of the Year Award, acknowledging the vital work of locum pharmacists especially during the pandemic,” Dr Sim said.

 

“Sean has helped countless pharmacies across Australia and is always encouraging students and pharmacists to make the move to rural and locum pharmacy.”

 

Locumate co-founder Kavita Nadan also extended her congratulations to the winner.

 

“Locumate’s vision is to create a community for locums to feel supported and recognised for their ongoing efforts in helping our profession and being an integral part in delivering the vital healthcare services that pharmacy offers our communities.

 

“Through innovation and technology, Locumate is determined to change the experience for pharmacists and pharmacies in our industry.

 

PSA extends thanks to award sponsors, MIMS and Locumate, and looks forward to working with them again in 2023.

 

 

 

Media contact: Georgia Clarke 0487 922 176

The Pharmaceutical Society of Australia is the professional organisation of Australian pharmacists. PSA is the only government-recognised peak national body for pharmacists, representing all of the pharmacy profession in Australia.

 

 

PSA22: Viatris Pharmacy Student of the Year Announced

30 July 2022

 

 

The Pharmaceutical Society of Australia (PSA) is proud to congratulate Haylee Shaw from the University of Tasmania for taking out the 2022 PSA Viatris Pharmacy Student of the Year (PSOTY) award.

 

PSOTY awards recognise and celebrate outstanding pharmacy students by showcasing their counselling skills to the pharmacy profession and is a highlight of PSA’s annual flagship conference.

 

PSA National President Dr Fei Sim congratulated the winner.

 

“Congratulations to Haylee Shaw for successfully taking out the Pharmacy Student of the Year award,” Dr Sim said.

 

“This competition provides students the opportunity to demonstrate important skills such as gaining patient insights and patient understanding, active listening and skills that support positive patient outcomes.

 

“PSA is dedicated to making pharmacy an attractive career path for young people and celebrating success regardless of where you are in your career.

 

“Each of the students who participated in the PSOTY competition has demonstrated impressive professionalism, skill, and dedication. PSA wishes them the best in what I’m sure will be successful careers as pharmacists.”

 

Haylee says she has always had an interest in pharmacy and is excited to network and learn from other pharmacists.

 

“I have always admired the accessible nature of the pharmacy profession. The ability to provide evidence-based advice and quality use of medicines to any member of the community without cost that is something that really attracted me to this career path.

 

“I entered this competition as I wanted to push myself and further my practical experience. I was also excited to be a part of the national conference and hear from likeminded peers and professional.”

 

Viatris Head of Business Development, Strategic Partnerships, Portfolio and Sourcing, Charbel Azzi, also reiterated their continued support for the next generation of Australian pharmacists.

 

“At Viatris, we see pharmacists as the custodians of medicine safety and efficacy. We’re delighted to renew our sponsorship of the Pharmacy Student of the Year Award this year to support the pharmacy professionals of the future.

 

“They play a vital role in empowering Australians to live healthier at every stage of life, a mission we share. I was heartened by the drive and dedication of all the winners. I was particularly inspired by Haylee’s exemplary patient counselling skills, and congratulate her for winning this year.”

 

The People’s Choice Award was presented to Chloe Woodward from Newcastle University. 


PSA extends thanks to the PSOTY award sponsor, Viatris, for their ongoing support of the event, and looks forward to working with them again in 2023.

PSA22: Guideline for pharmacists supporting Aboriginal and Torres Strait Islander peoples launched

30 July 2022

 

 

The Pharmaceutical Society of Australia (PSA) has today launched guidelines for pharmacists supporting Aboriginal and Torres Strait Islander peoples with medicines management, as part of PSA22.

 

The guidelines mark PSA’s ongoing commitment to improving Aboriginal and Torres Strait Islander health by enhancing medicines management. The principles included in the guideline are relevant to all current and future pharmacists, from those just starting their professional journey to those with years of experience working in the Aboriginal and Torres Strait Islander health sector.

 

PSA National President Dr Fei Sim said that the guidelines were a vital part of the pharmacy profession’s effort to improve the health and wellbeing of all Australians.

 

“PSA is proud to have worked with the National Aboriginal Community Controlled Health Organisation (NACCHO) to develop these guidelines, which will help pharmacists around Australia, in all practice settings, deliver the best care to Aboriginal and Torres Strait Islander patients,” she said.

 

“The guidance can be used as a tool to support balanced and professional decision making, and ensure that Aboriginal and Torres Strait Islander patients’ needs, beliefs and preferences are met in a culturally safe way.

 

“The guidance can be used as an educational resource to inform quality assurance processes, support better practice, and provide support when resolving disputes and ethical dilemmas.

 

“I thank everyone involved in developing the guidelines, in particular the writing group consisting of exceptional pharmacists A/Prof Faye McMillan, Hannah Mann, and Naomi Weier.”

 

Deputy CEO of NACCHO, Dr Dawn Casey, says that the guidelines offer practical and detailed information, as well as some challenging ideas.

 

“All pharmacists have Aboriginal and/or Torres Strait Islander patients as well as colleagues, business partners or family who we interact with, know and work alongside,” she said.

 

“We hope you enjoy the journey as you work through the guideline and appreciate the relationships and learning that takes place along the way. Aboriginal and Torres Strait Islander peoples’ rich and diverse cultures are part of Australia’s identity. There is so much knowledge and power in this cultural capital.”

 

A/Prof Faye McMillan launched the report this morning at PSA22.

 

“In your journey as a pharmacist, this guideline offers you an opportunity to develop professionally, expand your organisation or business’s impact, build relationships and grow professionally,” A/Prof McMillan said.

 

“This is an exciting opportunity for pharmacists around Australia to move toward a strength-based approach to Aboriginal and Torres Strait Islander health care.

 

“The last guide to providing pharmacy services to Aboriginal and Torres Strait Islander people was released in 2014, and I’m proud to have worked with PSA to update these to reflect today’s best practice.

 

The development of the Guideline for pharmacists supporting Aboriginal and Torres Strait Islander peoples with medicines management was supported by the Australian Government Department of Health.

 

The Pharmaceutical Society of Australia thanks all those who have contributed to the development of the guidelines.

 

The guidelines for pharmacists supporting Aboriginal and Torres Strait Islander peoples with medicines management can be read here.

 

 

 

Media contact: Georgia Clarke   M: 0410 505 315     E: georgia.clarke@psa.org.au

 

The Pharmaceutical Society of Australia is the professional organisation of Australian pharmacists. PSA is the only government-recognised peak national body for pharmacists, representing all of the pharmacy profession in Australia.

 

PSA22: Address by Federal Health Minister the Hon. Mark Butler MP

29 July 2022

 

Speech delivered at the Opening Plenary of PSA’s National Conference, PSA22 in Sydney. 

 

 

What a terrific new president you have elected. I was wondering when she was bragging about still being asked for ID – even trying to go into pubs and things – that was a bit annoying for someone my age.  Your first female national president and a woman of such capability. You should be feeling very proud of that address and I really hope that you enjoy your time as National President of this very significant organisation, and I look forward to working with you more.

 

Can I also acknowledge that we meet today on the land of the Gadigal people of the Eora nation and pay my respects to their elders past, present, and their young leaders who will be so important in future years.

 

Today of all days, after we received the Closing the Gap report yesterday, we must recommit ourselves to the drastically unfinished work of closing the gap in health outcomes and life expectancy between Indigenous and non-Indigenous Australians. There is still much, much to do. And I’m very proud as a member of the new government that is committed to the full implementation of the Statement from the Heart from Uluru. The first government of which, obviously, being the voice of the parliament is something that we’re committed to doing during this first term of what we hope to be a multiple term Labor government. So, thank you very much, Raymond for his acknowledgement.

 

Can I also acknowledge that I’m here with my good friend and close colleague, Emma McBride, who is only the eighth pharmacist ever elected to the Federal Parliament of Australia, I think we’ve had about 1200 MPs. New South Wales probably send 16 or 20 lawyers every election to Canberra. I’m legally trained so I’m not going to go too far into that. We’ve got to do better than eight pharmacists. And Emma is only the first female pharmacist in the 121-year history of Parliament.

 
I have been enjoying – so much – working with her as part of our health team, and I am really looking forward to the work we will be able to do together. And you’re going to hear from Emma just after me. I was really delighted to receive this invitation to come and address you. Obviously, every health minister needs to engage very closely and deeply with the pharmacy sector, but I’m a Labor minister. And so being able to come to a conference where the staff – the workforce – for this sector comes together is particularly pleasing for me. And I’m really glad that it’s my first major speech to the health sector generally, but particularly with the pharmacy sector. I know also how excited you are to be able to come together for the first-time face to face after two and a half, really, really challenging years. So, I hope you obviously do productive work, but also to have the time just to reconnect. Apparently, there’s a great bar at the top of this building – which I’m not going to be able to be a part of – but I’m really glad you’re able to come together, face to face. And I want to acknowledge – as Fei did – the work that you’ve all put in over the last two and a half years. It’s been a really tough two and a half years.

 

And I was saying to Terry and Rhonda, that there’s been no more accessible place to go when people need some health advice, when they need some support, than a community pharmacy, arguably, even more accessible than their local hospital. And I know particularly in those early phases of the pandemic before vaccines that it was dangerous work. You were putting your personal health, even your lives on the line to continue the work that you’re trained to do, that you’re committed to do, and I don’t think we’ll ever forget that. It was an extraordinary contribution you made to the health and safety of your community and I acknowledge you for it.

 

As Fei said, you’ve kicked on in the different phases of this pandemic with more than 8 million COVID-19 vaccinations. You must be close to 50% of all the flu vaccinations this year, just demonstrating that we must continue to entrench the central role that pharmacists play in the National Immunisation Program. That is something that I am deeply grateful for.

 

I’m conscious also that you’re on the front line in that awful debacle over rapid antigen tests. I think I visited every pharmacy in my electorate in the western suburbs of Adelaide trying to find a rapid test for one of the members in my family over Christmas. And you were all just getting smashed and you shouldn’t have been. We should have been able to be ahead of the curve, order enough rapid tests to be able to get through that summer. But I know how much pressure you were on. And again, I acknowledge the way in which you dealt with that with good grace and continuing to provide as much good advice as you could to your communities.

 

But these are still challenging times, we’ve moved into undoubtedly a different place in this pandemic. But it’s a long way from over. Still, I think our latest official data shows that about 330,000 people officially contracted COVID over the last seven day. But the likely number is more than twice that. We look at the serum sampling, we’re doing the blood donations and the like which is just an extraordinary thing to think about really. We think that maybe 7 or 800,000 Australians are catching COVID, every single week. Right now, I haven’t looked at today’s numbers, but about five and a half thousand people are in hospital today with COVID – which is about one in 12 public hospital beds filled with COVID patients. Happily, the number of patients in hospital with influenza has dropped dramatically. But 5 and a half thousand, as you know, is an extraordinary pressure on hospital systems dealing with few little staff itself and a whole range of other respiratory illnesses, as well as all of the deferred care we’ve seen from the last couple of years. So, this is a very, very difficult period.

 

Again, on the upside, ICU numbers haven’t climbed as fast as broader hospitalisation numbers, they’re still well short of the numbers we saw in the first omicron wave over summer. But they are creeping up and the mortality data over the last few days has also started to creep up. Which is why when we came to government a couple of months ago, we wanted to bring some new energy into some of the elements of the pandemic response. I had been saying when we went into the election that there wasn’t enough information going out to the public about the critical importance of the third dose.

 

There was there was far too much, I think apathy around the importance of boosters, and a sense among too many members of the community that two doses were sufficient. I’ve said that the federal government should have been putting out strong information campaigns that you’re not fully protected, until you get your third dose at least. And if you’re at a particular age, which Fei is a long way from, you should have a fourth dose as well, which is why we started to roll that information campaign out. But still, there are about more than 5 million Australians who have effectively tapped out of the vaccine program. They’ve gone more than six months since they’ve had their second dose, that still haven’t had their third. And that number is only increasing by about 50,000 every week. It is proving very, very difficult to shift. And so, we have rolled out an information campaign on this. We’ve got targeted campaigns in First Nations communities. But there’s much more that I think we need to do around the third dose.

 

The story around the fourth dose is much better though, I have to say, we worked very hard to get the eligibility criteria standard for the fourth dose of the vaccine. And since that came into operation a couple of weeks ago, as you know better than me, fourth dose numbers have skyrocketed. I tried to get into my pharmacy on Saturday to get my fourth dose and I couldn’t. He was overflowing. We’ve had more than half a million people get a fourth dose every week since we made that change. That is a wonderful result. And it is going to prevent a whole lot of severe disease, because those fourth doses have been taken by people overwhelmingly over the age of 50, including over the age of 65.

 

The expansion of antiviral eligibility is also something we wanted to do very much, which is why for the first time, I think the Commonwealth, we actually put a submission before PBAC to expand that eligibility because for some reason, the drug companies involved weren’t willing to do that. And I’m glad that PBAC did expand that eligibility, we began seeing prescription numbers climb by almost 200% since that decision. The week before the decision about 13,000 scripts were filled for either Lagevrio or Paxlovid. The next week, it was 30,000. Well over double that. The next week, it was 32,000. I love to see that number continue to increase. You’re playing such a critical role in doing that.

 

And the other thing that I said when I came to office was that I wanted some more energy around vaccination rates in aged care facilities. At that time, only about 50% of residents had received their fourth dose which we know is going to be so critical for the most vulnerable members of our community. And since starting to bring some new energy, getting repeat visits back to those facilities, that number has climbed to 80 percent which I’m much, much more happy with.

 

As you know, expanding PBS approvals for Lagevrio and Paxlovid is critical to expanding access. Without the PBS listing those medicines cost about $1,000, which I know some people have been paying – they’re that keen to get it if they can afford it – but most Australians can’t even come close to affording $1000. So, getting that listing, getting it down to $42.50, or even $6.80 at for concessionals was absolutely critical and it just reminds us again, what a wonderful system we have in the PBS.

 

I said yesterday to Peter Dutton, who I’ve sparred with for some years – having been the Health Minister for four years under Kevin Rudd and Julia Gillard – over health policy, I said how proud we are of our legacy as the Labor party and health. The twin pillars of universality in this country were hard fought. Most of us would remember the fights over universal health care through Medibank and then Medicare. We fought it for decades, and now it’s firmly entrenched as part of our social fabric. It wasn’t easy.

 

And the PBS wasn’t easy, either. John Curtin and then Ben Chifley fought hard to get this and it took two more high court challenges, two referendums, constitutional changes in a pitched battle to what was in then British Medical Association, the BMA, the Liberal Party, and many others, took really 15 or so years for it to become what it is today, which is a genuinely universal system, perhaps, I think, the best medical system pound for pound, in terms of bang for buck, that we have in the world. And I’m absolutely committed to making sure it works as well as it possibly can into the future as well. But for general patients, it is still a squeeze.

 

I know talking to pharmacists who have to deal with general patients coming through their door all the time, that many, many thousands of people, given the price pressures they’re facing in their households today are often making really tough decisions about which script they get filled, particularly if there are multiple scripts. Don’t take my word for it, the ABS said that around 900,000 patients every year are going without a script that their doctor has said to them is critical to their health. And they come in and I’ve heard you tell me these stories. And they say, well, I’ve got these two or three scripts, which one do you think is most important? And they might take the one that gives them the most immediate relief or pain relief script, for example, and forego the one that’s going to be really important for their longer-term health. Well, we’ve got to do better than that, which is why we’re committed to slashing the price of medicines for general patients on first of January.

 

We will do that, from $42.50 down to $30. It is a substantial fiscal commitment in a tight budget, but one particularly given price pressures on households right now is something that we’re committed to doing.

 

And we said at the election as well we will ensure that no patient is worse off. I’m aware of the discounting arrangements that operate in different pharmacies, and we’re committed, and I’m designing the legislation this way, we’re committed to making sure that scripts that are currently discounted, will still be able to be discounted, given the change in the in the general patient rate, and still count towards the threshold, towards the safety net.

 

In the same vein, I’m really pleased also that we’ve been able to already deliver on our commitment to provide much better support to people living with type one diabetes and wanting to access the extraordinary technology we have available to us now with constant glucose monitoring.

 

I was the Parliamentary Secretary for Health not last decade, the decade before last, when we in the Rudd Government introduced the first insulin pump program. That was seen then as just extraordinary technology. And it was. It really was quite life changing. But I’ve seen the changes in the last decade or more, and I’ve also seen the pressure placed on people who aren’t covered by the current program. Young kids, concession cardholders. The pressure placed on them at 18 to find four or $5,000 every year to pay for their CGM’s. And so, I’m really pleased that we’re able on the first of July – it took some pretty quick going – to on the first of July, to be able to bring in our new arrangements that everyone with type one diabetes – about an additional 80,000 people or so – will be able to access CGM technology by paying just a relatively small co-payment of $32.50 every month. Obviously, everyone covered by the old program remain covered. But again, this is a life changing innovation.

 

Now when I first met with your new president, which was last week, or the week before, and Mark as well, she asked me to do three things. And I just want to go through those three things. Three must be an important number for you. Three stories, and your three asks of the new federal government.
The first is around the commitment we’ve made to pharmacy and aged care. And it’s a really exciting commitment. I talked to Fei a little bit about this. She expressed her excitement about not just being able to deliver services for some of the most vulnerable members of our community, people who’ve worked so hard for decades and paid their taxes, raised their families and built this community we’re lucky enough to live in. From a pharmacy perspective, it’s just continuing to expand your vocation, your profession, not just community pharmacy, not just hospital pharmacy, that now recognising the ability to move into geriatrics, gerontology, into aged care, to become a new branch of your profession. I understand how exciting that is for you.

 

But it’s no secret from the perspective of residents themselves. That medication use and abuse has been a major issue in residential aged care for a long time. I’ve dealt with aged care for almost 30 years in different capacities. It’s an area I feel very, very close to. And I’ve seen the change over those 30 years as I’ve visited aged care facilities. When I started, many people had cars and would leave the facility and go shopping that might be there for 15, 20 years. The sort of cohort you now see in retirement villages, it’s very different cohort as you know, right now, but when I was Julia Gillard’s Minister for Aged Care more than a decade ago, you’ll remember, there was a lot of public discussion about the overuse of anti‑psychotics in residential aged care. Anti-psychotics are often prescribed, as someone was transitioning into a facility to deal with the distress that they were feeling, particularly if they were affected by dementia, particularly behavioural symptoms. A prescription that was intended to be short-lived and was often not being reviewed and certainly not been de-prescribed. And there was quite substantial public reporting about the cardiac impacts that was having as well. And I was absolutely struck by a roundtable that I convened about how we would deal with this, and one of Australia’s leading geriatricians told me when we were talking about the prevalence of polypharmacy in residential aged care, that he had come across a resident who had 43 scripts, different medicines, 43. None of them had been reviewed, and just kept accreting and accreting, and accreting.

 

We’ve got to do better, we have been doing better over the last decade, but the Royal Commission recognised that we needed to do better still. And that to do better still, we needed to tap your skills, we needed to tap your training and your experience. And I’m absolutely committed to delivering on that recommendation – Recommendation 38 of the Royal Commission.

 
And with this in mind, I’m very pleased to announce that today, a consultation paper will be launched on the department’s aged care engagement hub to start that process and ensure that we’re able to deliver on this commitment of $345 million. As a fraction of a million dollars, I’d forgotten about that, $345 million as we committed to do. And it means that we’re going to have to engage in the process of pretty quick co‑design. And that’s going to involve close engagement with the PSA as well as obviously, other groups like the Guild, residential aged care providers, unions, consumers, and probably also Primary Health Networks. The key issues that we’re going to talk about are well known to you. We’ve got to define the role of the onsite pharmacist, we’ve got to ensure that we’re very clear about training requirements for those pharmacists who will be working in residential aged care. Funding models will be important, and also ensuring the greater to measure health outcomes, and ensure that this investment delivers better outcomes for people living in residential aged care. I really look forward to the PSA’s active engagement in this process. Fei and Mark and I have already had a good deep discussion about the PSA’s views on this, because I know that you’ve done some of the deepest work in this area with some of your reports, which Fei was able to give to me to have a read of.

 

Which brings me to the second of Fei’s points. There are obviously also a whole range of aged care programs that you all work very hard on, as do your colleagues that are set out in the community pharmacy agreement or CPA7. When I speak of CPA7 I know having been involved in some of the earlier iterations when we were last in government, I know what a significant advance it was for the PSA to become a signatory to that agreement. And in my view, it was a good advance, it was an overdue and welcome advance, and it’s one that I can’t see any reason not to reflect as we move into the negotiations of CPA8, which will be in the second half of this term of Parliament.

 

Friends there’s much more I’d like to talk about, well, perhaps if I had the opportunity to chat with you about it in the sky bar, I just unfortunately don’t have the time, so I really want to acknowledge very quickly, the PSA’s work with the federal government and the Department of the take home Naloxone program. My state of South Australia was part of the pilot of that program, and I was quite flabbergasted by the results. Just the pilot showed that three lives were being saved every day by this program, it’s just really jaw dropping how effective something relatively simple can be, and really pleased to see that rollout into the non-pilot states as well. But it wouldn’t have been as successful a pilot in the program without the PSA’s close engagement. So, thank you for that. And I’m really pleased that we’re going to see that rollout right through the country and save many, many hundreds of lives.
 

I also know your deep interest in the review of the national medicines policy. I understand Michael Kidd is coming to talk to you a little later on today. I’ve known Michael for a very long time. I worked closely with him in in blood borne viruses and STIs, and a range of other areas when I was a health minister more than a decade ago. He’s a terrific fellow. I’m really pleased to announce that I’ve asked him to restart the review of the NMP. He’ll talk to you a little bit more in detail about that later today.

 

And I’m keen to have not today, perhaps, but I really think we need some deeper discussion about workforce in health. I mean, you’ll have read the papers, looked at the TV, every sector of the economy is dealing with workforce shortages right now. The closure of the borders for a country that for 20 years have relied so heavily on international workers in every sector has had a profound impact on our economy. We see it everywhere. But there is no more serious impact than in health – using that in the broadest sense of the word – we’re seeing it in our hospitals. We’re seeing it in general practice. We’re seeing it in aged care. And I know we’re seeing it from pharmacy as well, a number of you have told me about that. We need a really deep discussion about how we deal with some of those short-term challenges that will start to ameliorate as you open the borders, and some of the real structural challenges we have in the sector as well.

 

Terry and Rhonda and I were talking about this earlier, and I’ve got a very clear view about this, which I’ve said publicly on a number of occasions. It just doesn’t make sense to me as an Australian, but also as a health minister, that the enormous investment the community makes in training hundreds of thousands of health professionals is limited by not allowing people to operate at the top of their scope. It doesn’t make sense to me as demand for healthcare is climbing dramatically, leaving aside the impact of COVID, and we continue to have constrained supply of health workforces, not to have every single healthcare professional – whether they are doctors, nurses, allied health professionals or pharmacists working as close as possible to the top of their scope of practice. Now I know as well as you do that that is a contested proposition. And it’s not easy to step through that proposition without enlightening turf wars that can become very debilitating for community confidence as well as substantive outcomes. It’s something we tried to do when we were last in government. Minister Nicola Roxon was particularly passionate about it. And for the Labor Party, I see it very much as unfinished business, something I do want to come back to.

 

Health Workforce Australia was a really strong initiative for that former government. The abolition of HWA by Tony Abbott was probably predictable, but unfortunately wasn’t followed up with some alternative way in which could plan medium and long term for the health workforce needs of our country. I’m open to what that structure might look like. I haven’t committed particularly to any particular model. But we do need to have this very broad deep discussion because if we think it’s hard to see a doctor, hard to get into a pharmacist when some of you are struggling with your workforce challenges, you think that’s hard now, if we don’t get some of these structural challenges right, five or 10 years down the track, it’s going to be even harder. The PSA is going to be a really important partner in that discussion.

 

I want to thank you again for the invitation to come and talk to you. I really wish you all the very best for the rest of your conference over the weekend, and to a frank and productive relationship with the PSA as my time as Minister.

 

Thank you very much.